WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

ESPERION Q4 & FY 2021 EARNINGS PRESENTATION

FEBRUARY 22, 2022

FORWARD-LOOKNG STATEMENTS & DISCLOSURES

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, restructuring and current and planned operational expenses, future operations, commercial products, clinical development including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law.

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

BUSINESS OVERVIEW

SHELDON KOENIG, PRESIDENT AND CEO

ESPERION®

Q4 2021 & RECENT HIGHLIGHTS

- CLEAR Outcomes trial reached 90% MACE Accumulation in February
- U.S net product revenue of NEXLETOL® and NEXLIZET® recognized growth of 12% from Q3 2021 to $12.2 million in Q4 2021
- Demonstrated sequential prescription growth of 9% from Q3 2021 with over 70,000 cumulative patients
- Strengthened capital position with $209 million financing, securing path to CLEAR Outcomes top-line and the foreseeable future following those results
- Ended Q4 2021 with $309.3 million in cash, cash equivalents, restricted cash and investment securities
- Announced transformative strategic plan and expense structure to support the long-term growth of NEXLETOL® and NEXLIZET®



U.S. REVENUE OF $12.2 MILLION

FOCUSED ON DRIVING CONSISTENT GROWTH AS WE APPROACH CVOT RESULTS

Quarterly Franchise RPE Trend



Weekly Franchise RPE Trend Since Launch [1]



1. Through February 11, 2022

*Based on Symphony data
RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

ESPERION

CLEAR OUTCOMES STRATEGICALLY DESIGNED

ACHIEVED 90% MACE ACCUMULATION IN FEBRUARY 2022; TOPLINE EXPECTED Q1 2023

- A 14,014-patient randomized, double-blind, placebo-controlled clinical trial with median follow up anticipated to be 3.75 years
  - One of largest and longest of any non-statin trial
- Unique patient population where included patients must have all of the following:
  - Established ASCVD or at high-risk of developing ASCVD
  - LDL-C ≥100 mg/dL on maximally-tolerated lipid-lowering therapy including no statin
- Primary outcome: composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization
- Event-driven trial that will continue until 1,620 patients experience a primary endpoint
  - Minimum of 810 hard ischemic events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke); Achieved >100% MACE-3
  - Minimum treatment duration of 36 months and a projected median treatment exposure of 42 months

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

FINANCIAL UPDATE

RICK BARTRAM, CFO

FINANCIAL STRENGTH TO DELIVER GROWTH

RECENT FINANCING & ADJUSTED COST BASE EXTENDS CASH RUNWAY

$12.2 M Q4 2021 U.S. Product Revenue

$309.3 M Q4 2021 Cash, Cash Equivalents, Restricted Cash & Investment Securities Available-for-Sale [1]

>$1.2 B Future Ex-U.S. Collaboration Milestones from Daiichi Sankyo & Otsuka

Key Financial Data

FY 2021 Op Ex Actual [2]	$305 Million
FY 2022 R&D Guidance	$100 - $110 Million
FY 2022 SG&A Guidance	$120 - $130 Million
FY 2022 Op Ex Guidance [3]	$220 - $240 Million
Q4 2021 Common Shares Outstanding [4, 5]	60.9 Million

1. Includes $50M of restricted cash and $209M net proceeds from December Follow-on offering
2. Includes $24M of non-cash stock-based compensation expense
3. Includes $25M of anticipated non-cash stock-based compensation expense
4. After accounting for 2.0 million treasury shares to be purchased in the $50M prepaid forward transaction as part of the November 2020 convertible debt financing
5. Inclusive of approximately 32.1M shares issued for December Follow-on offering

ANTICIPATING INCREASED FOCUS ON CARDIOVASCULAR DISEASE PREVENTION

Cardiovascular disease was worsened by the COVID-19 pandemic[1,2]

- Lockdowns led people to postpone procedures and skip diagnostic tests, as well as avoid seeking care for health emergencies
- COVID-19 survivors across the globe have been left with a 63% higher risk for heart attack and a 52% higher risk of stroke
- Risk of cardiovascular problems was increased for all people, no matter age, gender, or health status

ESPERION is a leading biotech in cardiovascular disease prevention

- Increasing access to NEXLETOL® and NEXLIZET®
- Completing the CLEAR Outcomes trial
- Continuing to progress our pipeline that includes an oral PCSK9 inhibitor and an ACL inhibitor platform

1. As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years | tctmd.com
2. https://www.science.org/content/article/covid-19-takes-serious-toll-heart-health-full-year-after-recovery

THANK YOU

ESPERION

IMPORTANT SAFETY INFORMATION

NEXLETOL® SAFETY PROFILE

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile – please see https://pi.esperion.com/nexletol/nexletol-pi.pdf

NEXLIZET® SAFETY PROFILE

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile - see https://pi.esperion.com/nexlizet/nexlizet-pi.pdf